SCHEMBL7324893

SCHEMBL7324893

CCC(=O)Nc1cccc2c1CCC(NC(=O)CC)C2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 8/20 0.65
MTNR1B P49286 8/20 0.65
CYP1A2 P05177 2/20 0.59
ALOX15 P16050 2/20 0.59
MAPT P10636 1/20 0.59
CYP2C9 P11712 1/20 0.59
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
ACHE P22303 2/20 0.50
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP2C19 P33261 1/20 0.45
DRD2 P14416 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7335952 0.93 MTNR1A (0.60) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL7326549 0.93 MTNR1A (0.62) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL23917191 0.85 ALDH1A1 (0.52) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL7331004 0.83 MTNR1A (0.60) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL7333316 0.83 MTNR1A (0.67) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL30089783 0.81 MTNR1A (0.84) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL2597485 0.81 MTNR1A (0.84) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL2351965 0.81 MTNR1A (0.84) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL827706 0.79 MTNR1A (1.00) MTNR1AMTNR1BCYP1A2ALOX15MAPT
SCHEMBL2597383 0.79 MTNR1A (1.00) MTNR1AMTNR1BCYP1A2ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5250678-A For autoimmune, infectious diseases, organ transplant rejection; skin diseases, antiinflammatory agents MERCK & CO., INC. (US) 1993-10-05 US disclosed
US-5196454-A METHOD OF TREATING DISORDERS OF THE DOPAMINERGIC SYSTEMS USING 2,5-DIAMINOTETRALINES BOEHRINGER INGELHEIM KG (DE) 1993-03-23 US disclosed
EP-0402923-A2 2,5-Diaminotetralines, process for their preparation and their use as medicine BOEHRINGER INGELHEIM KG (DE) 1990-12-19 EP disclosed